Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

NCT04672005 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: Folfirinox alternating with Gemcitabine-nab-Paclitaxel

Sponsor

Lyudmyla Berim